These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72. Combinatorial Approaches to the Treatment of Advanced Melanoma. Munhoz RR; Postow MA Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771 [TBL] [Abstract][Full Text] [Related]
73. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Queirolo P; Picasso V; Spagnolo F Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484 [TBL] [Abstract][Full Text] [Related]
74. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004 [TBL] [Abstract][Full Text] [Related]
75. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. Johnson AS; Crandall H; Dahlman K; Kelley MC J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743 [TBL] [Abstract][Full Text] [Related]
76. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096 [TBL] [Abstract][Full Text] [Related]
77. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Queirolo P; Spagnolo F Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583 [TBL] [Abstract][Full Text] [Related]
78. Treatment of Recurrent Melanoma Following Adjuvant Therapy. Malissen N; Grob JJ Am J Clin Dermatol; 2023 May; 24(3):333-341. PubMed ID: 36890427 [TBL] [Abstract][Full Text] [Related]
79. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Jung T; Haist M; Kuske M; Grabbe S; Bros M Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576054 [TBL] [Abstract][Full Text] [Related]